Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4664-4672

  Martín Peña, Almudena ^a,b   Gil Navarro, M Victoria ^a   Aguilar Guisado, Manuela ^a,b   Espigado, Ildefonso ^a,b   De Pipaón, Maite Ruiz Pérez ^a,b   Falantes, José ^a   Pachón, Jerónimo ^a   Cisneros, José M ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSIS DRIVEN ANTIFUNGAL THERAPY; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EMPIRICAL ANTIFUNGAL THERAPY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PATIENT SELECTION; PERSISTENT FEBRILE NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIFUNGAL AGENTS; FEBRILE NEUTROPENIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84884214955     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00723-13     Document Type: Article

References (34)

1. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. 2006. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologicae 91:1068-1075.
2. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. 1982. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72:101-111.
3. Vento S, Cainelli F. 2003. Infections in patients with cancer undergoing chemotherapy: etiology, prevention, and treatment. Lancet Oncol. 4:595- 604.
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-AH, Wingard JR, Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52:e56-e93.
5. Link H, Böhme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW. 2003. Antimicrobial therapy of unexplained fever in neutropenic patients- guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann. Hematol. 82(Suppl 2):S105-S117.
6. De Pauw BE, Sable CA, Walsh TJ, Lupinacci RJ, Bourque MR, Wise BA, Nguyen B-Y, DiNubile MJ, Teppler H. 2006. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl. Infect. Dis. 8:31-37.
7. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.
8. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J. 2005. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41:1242-1250.
9. Maertens J, Deeren D, Dierickx D, Theunissen K. 2006. Preemptive antifungal therapy: still a way to go. Curr. Opin. Infect. Dis. 19:551-556.
10. Cherif H, Kalin M, Björkholm M. 2006. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? Eur. J. Haematol. 77:288-292.
11. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M. 2009. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48:1042-1051.
12. Cisneros JM, Espigado I, Rivero A, Lozano de León F, Parra J, Collado AR, Lomas JM, Pachón J. 2005. Empirical antifungal therapy in selected patients with persistent fever and neutropenia. Enferm. Infecc. Microbiol. Clin. 23:609-614. (In Spanish.)
13. Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, Parody R, Pachón J, Cisneros JM. 2010. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant. 45:159-164.
14. Aguilar-Guisado M, Martin-Pena A, Espigado I, Ruiz Perez de Pipaon M, Falantes J, De la Cruz F, Cisneros JM. 2012. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologicae 97:464-471.
15. Al-Badriyeh D, Liew D, Stewart K, Kong DCM. 2009. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J. Antimicrob. Chemother. 63:197-208.
16. O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. 2009. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 12:666- 673.
17. Lilford RJ, Pauker SG, Braunholtz DA, Chard J. 1998. Decision analysis and the implementation of research findings. BMJ 317:405-409.
18. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K. 2001. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann. Intern. Med. 135:412-422.
19. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340: 764-771.
20. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.
21. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. 2000. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. 108:282-289.
22. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. 1996. Cost-effectiveness in health and medicine. Oxford University Press, Oxford, United Kingdom.
24. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. 2002. What is an efficient health technology in Spain? Gac Sanit. 16:334-343. (In Spanish).
25. Briggs A. 1999. Economics notes: handling uncertainty in economic evaluation. BMJ 319:120.
26. Maertens JA, Nucci M, Donnelly JP. 2012. The role of antifungal treatment in hematology. Haematologicae 97:325-327.
27. Al-Badriyeh D, Liew D, Stewart K, Kong DCM. 2009. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J. Antimicrob. Chemother. 63:1276-1285.
28. Al-Badriyeh D, Liew D, Stewart K, Kong DCM. 2012. Pharmacoeconomic analysis of voriconazole versus caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses 55:244-256.
29. Stam WB, Aversa F, Kumar RN, Jansen JP. 2008. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health 11: 830-841.
30. Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG. 2007. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin. Drug Invest. 27:233- 241.
31. Tan BH, Low JGH, Chlebicka NL, Kurup A, Cheah FK, Lin RTP, Goh YT, Wong GC. 2011. Galactomannan-guided preemptive versus empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int. J. Infect. Dis. 15:e350 -356.
32. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, De Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
33. Drummond MF, Sculpher MJ, Torrance GW. 2005. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, United Kingdom.
34. Sculpher M, Fenwick E, Claxton K. 2000. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 17:461-477.